DEFN14A: Lifeway Foods Proxy Battle: Smolyansky Seeks Board Overhaul

Edward Smolyansky, a major shareholder, is soliciting proxies to elect two new directors and establish a committee for strategic review at Lifeway Foods' 2025 Annual Meeting, citing board ineffectiveness and mishandling of a Danone acquisition offer.

Summary

• Edward Smolyansky, a long-time shareholder and former executive, is soliciting proxies to elect himself and George Sent as directors at Lifeway Foods, Inc.'s 2025 Annual Meeting on December 29, 2025.
• Mr. Smolyansky controls approximately 16.3% (2,484,975 shares) of the company's outstanding common stock.
• The solicitation also includes a non-binding shareholder proposal to form a Board committee to review management, strategic plans, and strategic alternatives.
• Mr. Smolyansky urges shareholders to vote FOR his nominees and five other named individuals, and WITHHOLD votes for current directors Dorri McWhorter, Jason Scher, and Julie Smolyansky (CEO).
• The solicitation highlights the Board's rejection of Danone's acquisition proposals of $25.00 and later $27.00 per share in 2024, after which Lifeway's share price declined by 16.7% by November 21, 2025.
• Danone initially intended to support Mr. Smolyansky's consent solicitation to replace the entire Board but later entered a Cooperation Agreement with Lifeway, requiring Lifeway to add four new independent directors and Danone to vote in favor of the company's nominees for the 2025 and 2026 annual meetings.
• The filing details ongoing legal disputes, including Danone's lawsuit against the Board for alleged breach of fiduciary duty related to a 283,337 share issuance to CEO Julie Smolyansky, and Edward Smolyansky's indemnification dispute for $210,000.
• Mr. Smolyansky intends to vote FOR proposed amendments to the Articles of Incorporation regarding director exculpation and indemnification, and FOR the ratification of Grant Thornton LLP as the independent auditor for fiscal year 2025.
• He intends to vote AGAINST the non-binding advisory vote on executive compensation and FOR an annual frequency for future say-on-pay votes.
• Total estimated expenses for this proxy solicitation are approximately $400,000, with Saratoga Proxy Consulting receiving up to $75,000.

Sentiment

Score: 4

Explanation: The filing reveals significant internal conflict, ongoing litigation, and a contentious proxy battle, which are generally negative for investor confidence and operational stability. The rejection of a substantial acquisition offer and subsequent share price decline further contribute to a negative sentiment regarding current management and board effectiveness. While the proposed changes aim for improvement, the current state of affairs is highly disruptive.

Positives

• The proxy solicitation aims to improve corporate governance and strategic oversight by electing new independent directors.
• The proposed non-binding shareholder proposal for a strategic review committee could lead to a more objective evaluation of the company's direction and management performance.
• The Cooperation Agreement with Danone mandates the addition of three new independent directors within 30 days and a fourth within 45 days, and an independent chair, which could enhance board independence.
• Edward Smolyansky's significant ownership stake (16.3%) aligns his interests with long-term shareholder value.

Negatives

• The current Board rejected Danone's acquisition offers of $25.00 and $27.00 per share, leading to a 16.7% decline in Lifeway's share price by November 21, 2025.
• Ongoing litigation, including Danone's lawsuit against the Board for alleged breach of fiduciary duty and Edward Smolyansky's indemnification dispute, indicates significant internal conflict and potential legal costs.
• The Board's extension of the Shareholder Rights Agreement is viewed by Mr. Smolyansky as subverting shareholder rights.
• The issuance of 283,337 shares to CEO Julie Smolyansky and a $2,000,000 retention bonus to her are contentious, with Danone alleging breach of the Shareholder Agreement and fiduciary duty.
• Edward Smolyansky has a history of eight late Form 4 filings since January 31, 2021, raising questions about his compliance.

Risks

• Governance Instability: The ongoing proxy contest and internal disputes create uncertainty regarding the company's leadership and strategic direction.
• Litigation Costs and Outcomes: The Danone Shareholder Litigation and Mr. Smolyansky's Indemnification Dispute could result in significant legal expenses and adverse judgments for the company.
• Shareholder Rights: The extension of the Shareholder Rights Agreement could be perceived as entrenchment and may deter future acquisition offers.
• Strategic Misalignment: Disagreement over the company's strategic plan and alternatives, particularly after rejecting Danone's offers, could hinder long-term value creation.
• Management Effectiveness: Allegations of ineffective oversight and self-enrichment by the current board and management could impact operational performance and investor confidence.
• Reputational Damage: Public disputes and legal battles can harm the company's reputation among investors, customers, and employees.

Future Outlook

The filing indicates a future outlook focused on potential changes in corporate governance and strategic direction. If the shareholder nominees are elected and the non-binding proposal for a strategic review committee passes, the company could undertake an independent and objective evaluation of its management, strategic plan, and strategic alternatives. The Cooperation Agreement with Danone also mandates the addition of new independent directors and an independent chair, suggesting a shift towards enhanced board independence and oversight.

Management Comments

• "Edward Smolyansky believes that the Lifeway Board under incumbent leadership has been largely ineffective in its oversight of the Company’s management."
• "We believe the legacy directors prioritized self-enrichment or self-preservation, which cannot be overlooked."
• "Mr. Smolyansky believes the legacy directors are responsible for gross mishandling of a credible offer from its largest shareholder, Danone."
• "Mr. Smolyansky believes the legacy directors failed to remedy governance challenges, subverted shareholder rights by extending the expiration of the Shareholder Rights Agreement, and permitted the wasteful use of shareholder capital for litigation and other hostile acts toward investors."
• "Mr. Smolyansky believes that the election of the Shareholder Nominees will help the Company more effectively address the Company’s past failures regarding oversight, governance and performance, and will help ensure a path to long-term value creation for ALL shareholders."
• "Mr. Smolyansky believes that the Shareholder Nominees will be able to engage in an an independent and objective evaluation of the Company’s recent financial performance and the Company’s strategic alternatives."
• "Mr. Smolyansky believes that the Board has repeatedly failed to exercise proper oversight of Lifeway’s executive management team, including its chief executive officer, and that such failures directly resulted in the previously announced determination by Danone that it would no longer pursue an acquisition of Lifeway."
• "Mr. Smolyansky further believes that this decision materially harmed the ability of Lifeway’s shareholders to achieve liquidity for their shares at a meaningful premium to recent trading prices."

Industry Context

Lifeway Foods operates in the growing market for probiotic-based products and natural, "better for you" foods, where it is a significant player in the U.S. kefir market. The attempted acquisition by Danone, a major global food corporation, highlights the attractiveness of companies in this health-conscious food segment for larger industry players seeking growth and market share. The proxy contest itself reflects broader trends in shareholder activism, where large shareholders challenge incumbent management and boards over strategic direction, M&A decisions, and corporate governance, particularly when perceived shareholder value is not being maximized.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Lifeway's performance against global benchmarks.
• The rejection of a $27.00 per share cash offer from Danone, a major industry player, followed by a 16.7% share price decline, suggests a potential underperformance relative to market opportunities or peer valuations that might have accepted such an offer.
• The ongoing internal disputes and litigation, including allegations of breach of fiduciary duty and subversion of shareholder rights, indicate corporate governance practices that may fall below best-in-class industry standards for transparency and shareholder alignment.

Management Changes

Corporate Governance

Legal Proceedings

• Danone Shareholder Litigation: Filed by Danone North America against the Company and Board members in Circuit Court of Cook County, Illinois, Law Division (March 3, 2025). Allegations include breach of fiduciary duty by the Board (approving share issuance to Julie Smolyansky in violation of Shareholder Agreement) and breach of contract by the Company and Julie Smolyansky.
• Indemnification Dispute: Filed by Edward Smolyansky against the Company in Circuit Court of Cook County, Illinois, Chancery Division (April 4, 2025). Seeking indemnification for approximately $210,000 of expenses incurred in defending a prior lawsuit where the Company claimed Mr. Smolyansky violated fiduciary duties. The Company's claim in the prior lawsuit was voluntarily dismissed in February 2024.
• Shareholder Agreement Validity: Ongoing dispute regarding the validity and enforceability of the Stockholders Agreement dated October 1, 1999, among Danone, Mrs. Smolyansky, Mr. Smolyansky, and Julie Smolyansky. The Board's counsel and Julie Smolyansky have alleged its invalidity, while Danone maintains it is valid and enforceable. The Cooperation Agreement provides that Lifeway will comply with the Shareholder Agreement (without contesting or admitting its validity).

Related Party Transactions

• Julie Smolyansky (CEO): Received a one-time cash retention bonus of $2,000,000 on December 23, 2024. Repayment obligation terminates at 12.5% per three-month anniversary, subject to continued employment until December 20, 2026.
• Julie Smolyansky (CEO): Issued 283,337 shares of Common Stock on December 19, 2024, without Danone North America's consent, which Danone alleges was a breach of the Shareholder Agreement.
• Jason Burdeen (CEO's Chief of Staff, spouse of Julie Smolyansky): Total compensation in 2024 was $313,800, including a base salary of $200,000, a $100,000 short-term incentive cash bonus, $10,200 auto allowance, and $3,600 internet/telecommunication allowance.
• Jason Burdeen (CEO's Chief of Staff, spouse of Julie Smolyansky): Awarded 1,456 restricted stock units (RSUs) on January 10, 2024, vesting in tranches (486 vested Jan 10, 2025; 486 vest Jan 10, 2026; 484 vest Jan 10, 2027).
• Jason Burdeen (CEO's Chief of Staff, spouse of Julie Smolyansky): Awarded performance share units (PSUs) on January 10, 2024, with a target value of $40,000, based on Cumulative Revenue and Cumulative Adjusted EBITDA over a three-year performance period.

Stakeholder Impact

• Shareholders: Potential for enhanced long-term value creation if new directors and strategic review lead to improved performance. Risk of continued value erosion and legal costs due to ongoing disputes. Opportunity for liquidity at a premium was missed with Danone's rejected offers.
• Employees: Potential for changes in management and strategic direction could impact job security or organizational culture. The termination of the Senior Executive VP of Sales indicates existing instability.
• Customers: No direct impact mentioned, but stable leadership and clear strategy are generally beneficial for product development and market presence.
• Suppliers/Creditors: No direct impact mentioned, but financial stability and clear governance are important for business relationships.

Next Steps

• Shareholders to vote on director nominees and proposals at the 2025 Annual Meeting on December 29, 2025.
• Potential election of Edward Smolyansky and George Sent to the Board.
• Potential formation of a new Board committee to review management, strategic plan, and strategic alternatives, if the non-binding shareholder proposal passes.
• Lifeway to add three new independent directors within 30 days and a fourth within 45 days, and appoint an independent chair, as per the Cooperation Agreement with Danone.
• Lifeway and Danone to jointly seek to stay the pending Danone Shareholder Litigation.
• Lifeway to comply with the Shareholder Agreement (without contesting or admitting its validity).
• Company to file amended and restated articles of incorporation if proposed amendments for director exculpation and indemnification are approved.
• Edward Smolyansky may seek reimbursement of solicitation expenses from the Company.

Key Dates

Recommendation

The filing details a highly contentious proxy battle and significant corporate governance issues, including rejected acquisition offers, ongoing litigation, and disputes over executive compensation and share issuances. While the proposed changes by the dissident shareholder aim to improve oversight and strategic direction, the current environment of internal conflict creates substantial uncertainty and risk for investors. The mandated board refreshment via the Danone Cooperation Agreement offers some potential for positive change, but the overall situation suggests a period of instability. A "hold" recommendation is appropriate as investors await the outcome of the annual meeting and the implementation of governance changes, as the immediate future is clouded by these unresolved issues. The potential for long-term value creation exists if the governance issues are effectively resolved, but the short-term risks are elevated.

Keywords

Lifeway Foods, LWAY, proxy fight, shareholder activism, corporate governance, board election, Edward Smolyansky, George Sent, Danone, acquisition offer, kefir, probiotic products, SEC filing, DEFN14A, strategic review, executive compensation, shareholder rights agreement, litigation